BioSpace News Archive

Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming investor and industry conferences.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV).

IN8bio, Inc. today announced William Ho, CEO and co-founder, will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023, at 8:35 a.m. ET.

PDS Biotechnology Corporation today announced its investigational universal influenza vaccine PDS0202 demonstrated active neutralization across multiple influenza viruses.

89bio, Inc. today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the 2023 Cantor Global Healthcare Conference, being held in New York, NY on Tuesday, September 26, 2023 at 11:40 AM ET.

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal second quarter 2024 financial results on Wednesday, October 4, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC.

Acino announced that it has entered into an agreement to acquire M8 Pharmaceuticals, a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil.

Sanyou Bio’s consecutive wins reflect our clients’ trust, and our proven track record, raising expectations for our future.

Abbott (NYSE: ABT) announced today an agreement with Spain-based global biotech leader mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women’s health and respiratory diseases in emerging markets.